Strontium for Bone Density: Evidence and Safety

Strontium is an alkaline earth metal that behaves biochemically similarly to calcium due to comparable ionic radius and charge. In bone, strontium is incorporated into the hydroxyapatite crystal lattice in place of calcium, and at pharmacological doses it has documented effects on bone metabolism — simultaneously reducing bone resorption and stimulating bone formation. The pharmaceutical form strontium ranelate (Protelos, Osseor) was prescribed widely in Europe for osteoporosis before regulatory concerns about cardiovascular safety led to restricted use. Strontium citrate is the non-prescription supplement form used in North America. Understanding the distinction between strontium ranelate's evidence and strontium citrate's evidence is essential for an accurate picture.

How Strontium Affects Bone

Strontium's effects on bone are mediated through several mechanisms. Strontium ions activate the calcium-sensing receptor (CaSR) on osteoblasts, stimulating osteoblast proliferation and differentiation — a bone formation effect. Simultaneously, strontium reduces RANKL expression and increases osteoprotegerin (OPG) production, shifting the RANKL/OPG ratio toward reduced osteoclast activity — a bone resorption-inhibiting effect. This "dual action" (promoting formation while reducing resorption) distinguishes strontium from most osteoporosis medications, which predominantly work through one mechanism.

When strontium substitutes for calcium in bone hydroxyapatite, the crystal structure changes slightly — strontium-containing hydroxyapatite is denser than calcium hydroxyapatite because strontium (atomic mass 87.6) is heavier than calcium (atomic mass 40.1). This creates an important methodological issue for DEXA scanning: strontium's greater X-ray attenuation inflates apparent bone mineral density (BMD) measurements by a factor of 1.5–2.5x the actual mineral gain. This means BMD improvements seen in strontium clinical trials overstate the actual structural benefit.

The Strontium Ranelate Evidence

Strontium ranelate is the most extensively studied strontium compound. The landmark SOTI (Spinal Osteoporosis Therapeutic Intervention) and TROPOS (Treatment of Peripheral Osteoporosis) trials — large, 3-year RCTs in postmenopausal osteoporotic women — found significant fracture risk reduction: SOTI showed 41% relative risk reduction in vertebral fractures; TROPOS showed 16% relative risk reduction in non-vertebral fractures and 36% RRR in hip fractures (in the highest-risk subgroup). These are clinically significant reductions, and strontium ranelate was approved and prescribed in Europe.

However, post-marketing pharmacovigilance revealed a small but significant increase in serious cardiovascular events (MACE) with strontium ranelate — approximately 1.7-fold increase in non-fatal MI in the MEDAL program. The EMA restricted strontium ranelate to patients with severe osteoporosis who cannot use other medications and have no cardiovascular risk. The cardiovascular concern may be specific to the ranelate moiety, as no such signal has been identified in strontium citrate research (though strontium citrate simply lacks the large cardiovascular safety dataset of ranelate).

Strontium Citrate: What the Evidence Actually Shows

Strontium citrate is available as a supplement in North America, typically at 340–680 mg/day of strontium citrate (delivering ~200–400 mg elemental strontium). It is biologically plausible as a bone agent given strontium's mechanism, but the clinical evidence base is far smaller than for strontium ranelate. There are no large RCTs of strontium citrate with fracture endpoints. Case reports, observational data, and small interventional studies show BMD increases — but because strontium inflates DEXA measurements, these findings must be interpreted cautiously.

A practical approach to monitoring strontium supplementation effects: bone formation markers (P1NP, osteocalcin) and bone resorption markers (CTX, NTX) can indicate whether the biology is working correctly independently of DEXA artifacts. If formation markers rise and resorption markers fall, this suggests the desired pharmacological action is occurring.

Strontium vs Established Osteoporosis Treatments

For established osteoporosis requiring treatment, bisphosphonates (alendronate, risedronate), denosumab, and romosozumab have far more robust fracture reduction data than strontium supplements. Strontium citrate is best considered in the context of: bone density optimization alongside adequate calcium, vitamin D, magnesium, vitamin K2, and exercise in people with osteopenia or family risk; individuals who cannot tolerate bisphosphonates or prefer supplement-based approaches; and as adjunctive support alongside prescription therapy under physician guidance.

Dosing and Safety

Strontium citrate doses in supplements: 340–680 mg strontium citrate, typically taken at bedtime separated from calcium (calcium competes with strontium for absorption — strontium should be taken at least 2 hours after calcium). No UL has been formally established for supplemental strontium in North America. The cardiovascular concern from strontium ranelate has not been reproduced with strontium citrate, but given the limited safety database, individuals with significant cardiovascular disease should discuss strontium use with their physician.

FAQ

Does strontium supplementation really improve bone density? It almost certainly increases DEXA BMD measurements substantially, but some portion of this is artifact from strontium's greater X-ray density vs calcium. Based on strontium ranelate fracture data, there is likely genuine structural bone benefit — but the absolute improvement in fracture risk from strontium citrate at supplement doses is unknown.

Should I take calcium and strontium at the same time? No — take them separately. Calcium significantly reduces strontium absorption when taken simultaneously. The conventional recommendation is calcium with meals and strontium citrate at bedtime, achieving maximum absorption of both.

Is strontium the same as radioactive strontium-90? No. Strontium-89 and strontium-90 are radioactive isotopes of strontium — Sr-90 is a nuclear fallout product and Sr-89 is used in treating bone metastases. These are entirely different from the stable, non-radioactive strontium (primarily Sr-86 and Sr-88) in strontium citrate supplements.

Track your supplements in Optimize.